HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pseudotumor cerebri syndrome with different types of hormonal contraceptives in women of child-bearing age.

AbstractBACKGROUND AND PURPOSE:
There is a lack of comparative safety data on the risk of pseudotumor cerebri syndrome (PTCS) associated with different hormonal contraceptives. We sought to quantify the risk of PTCS associated with eight different types of hormonal contraceptives compared with oral levonorgestrel.
METHODS:
We conducted a retrospective cohort study, with a case-control analysis of 4 871 504 women aged 15-45 years in the period 2008-2015, using IQVIA Ambulatory Electronic Medical Records data in the USA. Patients who used nine different contraceptive agents including intrauterine levonorgestrel, medroxyprogesterone injection, etonogestrel/ethinyl estradiol vaginal ring and combination oral contraceptives (COCs) that contained ethinyl estradiol and the progestins levonorgestrel, norgestimate, desogestrel, norethindrone and drospirenone, were included. Diagnosis of PTCS was defined using the first International Classification of Diseases, 9th or 10th revision, code for intracranial hypertension in patients who had also received an imaging code in the 30 days prior to the index date.
RESULTS:
A total of 3323 PTCS cases and 13 292 matched controls were identified. No increase in risk was found when analysing intrauterine levonorgestrel or COCs containing desogestrel, norethindrone, drospirenone, norgestimate or norgestrel versus COC levonorgestrel. The adjusted incidence rate ratio for etonogestrel/etonogestrel/ethinyl estradiol vaginal ring and medroxyprogesterone suspension compared with levonorgestrel COC was 4.45 [95% confidence interval (CI) 1.98-9.96] and 2.20 (95% CI 1.33-3.64), respectively.
CONCLUSIONS:
This study found an elevated risk for PTCS among users of etonogestrel vaginal ring and medroxyprogesterone suspension when compared with oral levonorgestrel. Future studies are needed to confirm these findings.
AuthorsM Etminan, F Khosrow-Khavar, M Sodhi, B Carleton, L A Magee, H Tremlett, A Kezouh, C Sheldon
JournalEuropean journal of neurology (Eur J Neurol) Vol. 27 Issue 12 Pg. 2625-2629 (12 2020) ISSN: 1468-1331 [Electronic] England
PMID32810878 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2020 European Academy of Neurology.
Chemical References
  • Contraceptives, Oral, Combined
  • Contraceptives, Oral, Hormonal
  • Levonorgestrel
Topics
  • Adolescent
  • Adult
  • Contraceptives, Oral, Combined
  • Contraceptives, Oral, Hormonal (adverse effects)
  • Female
  • Humans
  • Levonorgestrel (adverse effects)
  • Middle Aged
  • Pseudotumor Cerebri (chemically induced, epidemiology)
  • Retrospective Studies
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: